Evidence map›Paper›PMID 40951285›Full record

ArticleResearch square2025

Next-generation Candida albicans recombinant Als3p and Hyr1p dual antigen vaccine for invasive Candida infections.

Shakti Singh, Eman G Youssef, Ashley Barbarino, Haley Hautau, Sunna Nabeela, Teclegiorgis Gebremariam, Sondus Alkhazraji, Gary Ostroff, Dennis Christensen, Terrence Cochrane and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Shakti SinghThe Lundquist Institute at Harbor-UCLA Medical Center.
Eman G YoussefThe Lundquist Institute at Harbor-UCLA Medical Center.
Ashley BarbarinoThe Lundquist Institute at Harbor-UCLA Medical Center.
Haley HautauThe Lundquist Institute at Harbor-UCLA Medical Center.
Sunna NabeelaThe Lundquist Institute at Harbor-UCLA Medical Center.
Teclegiorgis GebremariamThe Lundquist Institute at Harbor-UCLA Medical Center.
Sondus AlkhazrajiThe Lundquist Institute at Harbor-UCLA Medical Center.
Gary OstroffUniversity of Massachusetts Chan Medical School.
Dennis ChristensenCroda Inc.
Terrence CochraneVitalex Biosciences LLC.
Ashraf S IbrahimThe Lundquist Institute at Harbor-UCLA Medical Center.

Funding

The Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1M
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens SupplementR01AI141202 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2019 to 2023
$5.7M
Role of multi-drug resistant Candida auris Hyr1 / Iff-like proteins in virulence and their potential as vaccine targetsK01AI180591 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI Shakti Singh · 2024 to 2026
$405k
NCATS NIH HHS KL2 TR001882NIAID NIH HHS K01 AI180591NIAID NIH HHS R01 AI141202
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40951285
PMCPMC12425069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.